FDA Approves Amgen's UPLIZNA for Generalized Myasthenia Gravis, Expanding Treatment Options for Patients Living With Autoimmune Neuromuscular Disease
December 14, 2025
December 14, 2025
CHICAGO, Illinois, Dec. 14 -- The Muscular Dystrophy Association issued the following news release:
* * *
FDA Approves Amgen's UPLIZNA(R) (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease
NEW YORK -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the . . .
* * *
FDA Approves Amgen's UPLIZNA(R) (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease
NEW YORK -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the . . .